These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7591964)

  • 1. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
    Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
    Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
    Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
    Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
    Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
    Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
    Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
    Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta.
    Epling-Burnette PK; Wei S; Blanchard DK; Spranzi E; Djeu JY
    Blood; 1993 Jun; 81(11):3130-7. PubMed ID: 8499646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
    Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
    Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
    Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
    Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
    Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
    Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
    Atagi S; Sone S; Fukuta K; Ogura T
    Jpn J Cancer Res; 1992 Oct; 83(10):1088-94. PubMed ID: 1452461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of neuronal cells by culture supernatant of T lymphocytes triggered by anti-CD3 mAb followed by propagation in the presence of interleukin-2.
    Ishiguro M; Okada A; Asai K; Kojima K; Okada H
    Microbiol Immunol; 2016 Jan; 60(1):47-55. PubMed ID: 26616436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
    Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
    Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
    Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
    Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.